期刊
ONCOLOGY RESEARCH AND TREATMENT
卷 41, 期 5, 页码 282-285出版社
KARGER
DOI: 10.1159/000488918
关键词
Immunotherapy; Colorectal cancer; Metastatic; Adjuvant
类别
资金
- Deutsche Krebshilfe
- Sanofi
- Roche
- Merck
- GBA Innovationsfond
- BMS
- Amgen
- MSD
- Servier
- Sirtex
- Bayer
- Lilly
In contrast to other tumour types inhibitors of PD-1/-L1 or CTLA 4 have not yet shown relevant efficacy in unselected colorectal cancer. Based on the high mutational burden, deficient mismatch repair (dMMR) or microsatellite instable (MSI-H) tumours are yet the only subgroup, which is amenable to checkpoint inhibition. These tumours show relevant and durable responses in the refractory setting by PD-1/-L1 +/- CTLA 4 inhibition. Thus, ongoing phase 3 trials in this subgroup evaluate immunotherapy in the adjuvant setting as well as in the first line metastatic setting with or without chemotherapy. For the by far larger subgroup of non-dMMR/MSI-H patients (95% in the metastatic setting) combination regimen are urgently required, either with chemotherapy and/or molecular targeting drugs, local ablative treatments or other immunotherapeutic agents (e.g. CEA-TCB). (C) 2018 S. Karger GmbH, Freiburg
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据